These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 2305734)
1. Protective efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid-conjugate vaccine. Nelson WL; Granoff DM Am J Dis Child; 1990 Mar; 144(3):292-5. PubMed ID: 2305734 [TBL] [Abstract][Full Text] [Related]
2. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older. Greenberg DP; Vadheim CM; Bordenave N; Ziontz L; Christenson P; Waterman SH; Ward JI JAMA; 1991 Feb; 265(8):987-92. PubMed ID: 1992212 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. Hendley JO; Wenzel JG; Ashe KM; Samuelson JS Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597 [TBL] [Abstract][Full Text] [Related]
4. Haemophilus b disease after vaccination with Haemophilus b polysaccharide or conjugate vaccine. Frasch CE; Hiner EE; Gross TP Am J Dis Child; 1991 Dec; 145(12):1379-82. PubMed ID: 1669664 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age. Loughlin AM; Marchant CD; Lett S; Shapiro ED Pediatr Infect Dis J; 1992 May; 11(5):374-9. PubMed ID: 1630857 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the Haemophilus influenzae type b capsular polysaccharide conjugate vaccine in children after systemic Haemophilus influenzae type b infections. Kaplan SL; Zahradnik JM; Mason EO; Dukes CM J Pediatr; 1988 Aug; 113(2):272-7. PubMed ID: 3260943 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Dashefsky B; Wald E; Guerra N; Byers C Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519 [TBL] [Abstract][Full Text] [Related]
8. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation. Sood SK; Daum RS Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522 [TBL] [Abstract][Full Text] [Related]
9. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age. Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781 [TBL] [Abstract][Full Text] [Related]
10. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group. Wenger JD; Pierce R; Deaver KA; Plikaytis BD; Facklam RR; Broome CV Lancet; 1991 Aug; 338(8764):395-8. PubMed ID: 1678080 [TBL] [Abstract][Full Text] [Related]
12. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience with Haemophilus influenzae type b conjugate vaccines. Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855 [TBL] [Abstract][Full Text] [Related]
14. Finnish efficacy trials with Haemophilus influenzae type b vaccines. Eskola J; Peltola H; Käyhty H; Takala AK; Mäkelä PH J Infect Dis; 1992 Jun; 165 Suppl 1():S137-8. PubMed ID: 1588148 [TBL] [Abstract][Full Text] [Related]
15. Spectrum of disease due to Haemophilus influenzae type b occurring in vaccinated children. Hiner EE; Frasch CE J Infect Dis; 1988 Aug; 158(2):343-8. PubMed ID: 3261314 [TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of PRP-D Haemophilus influenzae type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30,000 children. Vadheim CM; Greenberg DP; Marcy SM; Froeschle J; Ward JI Pediatr Infect Dis J; 1990 Aug; 9(8):555-61. PubMed ID: 2235171 [TBL] [Abstract][Full Text] [Related]
17. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Hay JW; Daum RS Pediatr Infect Dis J; 1990 Apr; 9(4):246-52. PubMed ID: 2110651 [TBL] [Abstract][Full Text] [Related]
19. Studies on the combined administration of Haemophilus influenzae type B--diphtheria toxoid conjugate vaccine (PRP-D) and DTP. Gordon LK Dev Biol Stand; 1986; 65():113-21. PubMed ID: 3549393 [TBL] [Abstract][Full Text] [Related]
20. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. Murphy TV; Pastor P; Medley F; Osterholm MT; Granoff DM J Pediatr; 1993 Apr; 122(4):517-23. PubMed ID: 8463894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]